CEA Serum Rapid Test description:

"Export Use Only"
Diagnostic Automation/Cortez Diagnostics Inc. offers a Cancer CEA RapiDip Insta Test (5mm strip) which is a direct binding test for the detection of Carcinoma Embryonic Antigen (CEA) in serum. The CEA Rapid Test is used as an aid in the diagnosis of colorectal, breast, lung, and pancreas cancers. This Cancer CEA Rapid Test is for diagnostic use only.




Materials Provided with CEA Rapid Test Kits:
1. CEA Rapid Test Strips
2. Test Instructions

Materials required, not Provided:
1. Specimen collection container
2. Clock or timer




CEA Serum Rapid Test Background Information:
Carcinoembryonic antigen (CEA), first described in 1965 by Gold and Freeman, is a tumor-associated antigen characterized as an oncofetal glycoprotein. The OneStep CEA Test is a recently developed, sensitive and less complicated immunoassay of CEA. CEA was first present as a specific antigen for adenocarcinoma of the colon. More recent studies have demonstrated CEA presence in a variety of malignancies, particularly those involving ectodermal tissues of gastrointestinal or pulmonary origin. Small amounts have also been demonstrated in secretions from the colonic mucosa. Additionally, CEA-like substances have been reported in normal
bile from non-icteric patients. CEA testing can have significant value in the monitoring of patients. Persistent elevation in circulating CEA following treatment is strongly indicative of occult metastic and/or residual disease. A persistent rising CEA value may be associated with progressive malignant disease and poor therapeutic response. A declining CEA value is generally indicative of a favorable prognosis and good response to treatment. Measurement of CEA has been shown to be clinically relevant in the follow-up management of patients with colorectal, breast, lung, prostatic, pancreatic, ovarian, and other carcinomas. Follow-up studies of patients with colorectal, breast and lung carcinomas suggest that the preoperative CEA level has prognostic significance. CEA testing is not recommended as a screening procedure to detect
cancer in the general population; however, use of the CEA test as an adjunctive test in the prognosis and management of cancer patients is widely accepted. This CEA Rapid Test is used as an aid in the diagnosis of colorectal, breast, lung, and pancreas cancers




CEA Rapid Test Principle:[/]
CEA Rapid Test is used as an aid in the diagnosis of colorectal, breast, lung and pancreas cancers. The test is based on the principle of sandwich immunoassay for determination of CEA in serum. Monoclonal and polyclonal antibodies are employed to identify CEA specifically. This one step test is very sensitive and only takes 10-20 minutes. The sensitivity of the test can reach to 5μg/L. For additional details please refer to the instructions for use.




Notable features of the CEA Serum Rapid Test:
Reliable and inexpensive
Convenient and easy-to-understand directions
Clear preparation procedures
Simple and safe specimen collection directions
Comprehensive package of required materials and components
Rapid and accurate test results - 10 minutes

See CEA Serum Rapid Test Product Insert for specific details on preparation, procedures, quality control, and interpretation of test results.



Diagnostic Automation Inc. also offers other Cancer Rapid tests, and Cancer ELISA test kits. For more information about this CEA Serum Rapid Test or other Rapid tests, CLIA tests, IFA Kits, or ELISA test kits, please contact our Customer Service Representatives at 818-591-3030.



*Not to be sold, shipped, or distributed in the United States.